Ovarian Cancer: Can We Reverse Drug Resistance?
The treatment of ovarian cancer improved substantially with the introduction of platinum-based chemotherapy in the 1980s. In the 1990s, the results of randomisedcontrolled trials established paclitaxel in combination with a platinum agent as a standard initial chemotherapy for advanced ovarian cancer (1–3). However, over 90% of patients with advanced ovarian cancer will still subsequently die because of clinical failure of chemotherapy, i.e. drug resistance, resulting in an overall 5-year survival of only 30–40%. Clearly, there is a need for more progress in addressing this issue.
KeywordsOvarian Cancer Clin Oncol Epithelial Ovarian Cancer Ovarian Cancer Cell Nucleotide Excision Repair
Unable to display preview. Download preview PDF.